| Literature DB >> 29138605 |
Philip D Chilibeck1, Mojtaba Kaviani2, Darren G Candow3, Gordon A Zello4.
Abstract
The loss of muscle mass and strength with aging results in significant functional impairment. Creatine supplementation has been used in combination with resistance training as a strategy for increasing lean tissue mass and muscle strength in older adults, but results across studies are equivocal. We conducted a systematic review and meta-analysis of randomized controlled trials of creatine supplementation during resistance training in older adults with lean tissue mass, chest press strength, and leg press strength as outcomes by searching PubMed and SPORTDiscus databases. Twenty-two studies were included in our meta-analysis with 721 participants (both men and women; with a mean age of 57-70 years across studies) randomized to creatine supplementation or placebo during resistance training 2-3 days/week for 7-52 weeks. Creatine supplementation resulted in greater increases in lean tissue mass (mean difference =1.37 kg [95% CI =0.97-1.76]; p<0.00001), chest press strength (standardized mean difference [SMD] =0.35 [0.16-0.53]; p=0.0002), and leg press strength (SMD =0.24 [0.05-0.43]; p=0.01). A number of mechanisms exist by which creatine may increase lean tissue mass and muscular strength. These are included in a narrative review in the discussion section of this article. In summary, creatine supplementation increases lean tissue mass and upper and lower body muscular strength during resistance training of older adults, but potential mechanisms by which creatine exerts these positive effects have yet to be evaluated extensively.Entities:
Keywords: age; bench press; exercise; leg press; muscle; nutrition; sarcopenia
Year: 2017 PMID: 29138605 PMCID: PMC5679696 DOI: 10.2147/OAJSM.S123529
Source DB: PubMed Journal: Open Access J Sports Med ISSN: 1179-1543
Study characteristics and outcomes of research examining the influence of creatine in older adults with a resistance training program
| Study | Study population | Intervention | Duration | Outcome measure | Adverse events | Jadad score |
|---|---|---|---|---|---|---|
| Aguiar et al | n=18 (healthy women) | CR (5 g/day) or PLA | 12 wks | CR ↑ bench press, knee extension, bicep curl, fat-free mass, and muscle mass | Not reported and/or not collected | 4 |
| Alves et al | n=22 (healthy women) | CR (4×5 g/day for 5 days, 5 g/day thereafter) or PLA | 24 wks | ↔ leg press or chest press strength | No adverse events | 5 |
| Bemben et al | n=42 (healthy men) | CR (5 g/day), protein (35 g/day), protein (35 g/day) + CR (5 g/day) or PLA | 14 wks | ↔ upper or leg press strength, lean tissue mass | No adverse events | 4 |
| Bermon et al | n=32 (16 men, 16 women, healthy) | CR (20 g/day for 5 days followed by 3 g/day) or PLA | 52 days | ↔ leg press and chest press strength | No adverse events | 3 |
| Brose et al | n=28 (15 men; 13 women, healthy) | CR (5 g/day) or PLA RT=3 days/wk | 14 wks | CR ↑ lean tissue mass, isometric knee extension strength, isometric dorsiflexion strength in men | One gastrointestinal adverse event in the CR group, no kidney or liver adverse events | 3 |
| Candow et al | n=35 (healthy men) | CR (0.1 g/kg/day) or CR + protein (0.3 g/kg/day) or PLA | 10 wks | CR + CR + PRO conditions ↑ muscle thickness. | No adverse events | 4 |
| Candow et al | n=39 (17 men, 22 women, healthy) | CR (0.1 g/kg) before RT, CR (0.1 g/kg) after RT, or PLA | 32 wks | CR after RT ↑ lean tissue mass | No adverse events | 4 |
| Chilibeck et al | n=33 (healthy women) | CR (0.1 g/kg/day) or PLA | 52 wks | CR ↑ chest press strength | Gastrointestinal adverse events, CR =5 vs PL =2 | 5 |
| Chrusch et al | n=30 (healthy men) | CR (0.3 g/kg/day for 5 days followed by 0.07 g/kg/day) or PLA | 12 wks | CR ↑ lean tissue mass and leg press strength, leg press endurance, and average power (knee extension). | CR during loading phase increased gastrointestinal adverse events | 3 |
| Collins et al | n=16 (frail men and women) | CR (4 g/day) and whey protein (20 g/day) or whey protein | 14 wks | ↔ lean tissue mass, handgrip strength, timed up and go test, number of stands in 30 s | No adverse events | 4 |
| Cooke et al | n=20 (healthy men) | CR (20 g/day for 7 days; 0.1 g/day thereafter on training days) or PLA | 12 wks | ↔ lean tissue mass, bench press or leg press strength, myofibrillar protein, type I or II muscle fiber area, serum IGF-1 | No reporting of adverse events and/or not collected | 4 |
| Cornelissen et al | n=70 (66 men, 4 women with coronary artery disease or chronic heart failure) | CR (5 g/day) or PLA | 3 months | ↔ isometric or isokinetic knee extension strength | No adverse events including no reports of liver or kidney adverse events | 5 |
| Deacon et al | n=80 (50 men, 30 women with COPD) | CR (22 g/day for 5 days followed by 3.76 g/day) | 7 wks | ↔ shuttle walk distance, knee extensor work, isometric or isokinetic strength, lean tissue mass | No reporting of adverse events and/or not collected | 5 |
| Eijnde et al | n=46 (healthy men) | CR (5 g/day) or PLA | 26 wks | ↔ lean tissue mass, isometric strength | One CR group participant reported overuse trauma of the shoulder | 3 |
| Gualano et al | n=25 (9 men, 16 women with type 2 diabetes) | CR (5 g/day) or PLA | 12 wks | ↔ lean tissue mass, chest press, leg press, handgrip, and low back strength, chair stands in 30 s, timed up and go. | No adverse events | 5 |
| Gualano et al | n=30 (“vulnerable” women) | CR (20 g/day for 5 days; 5 g/day thereafter) or PLA | 24 wks | CR ↑ lean tissue mass and chest press strength | No adverse events including markers of kidney and liver function | 5 |
| Hass et al | n=20 (17 men, 3 women with idiopathic Parkinson’s disease) | CR (20 g/day for 5 days followed by 5 g/day); PLA | 12 wks | CR ↑ chest press strength, chair rise performance. | No adverse events | 3 |
| Johannsmeyer et al | n=31 (17 men, 14 women, healthy) | CR (0.1 g/kg/day) or PLA | 12 wks | CR ↑ lean tissue mass, men on CR reduced protein catabolism | No adverse events | 5 |
| Neves et al | n= 24 (postmenopausal women with knee osteoarthritis) | CR (20 g/day for 1 wk followed by 5 g/day) or PLA | 12 wks | CR ↑ physical function, stiffness subscales, lower limb lean mass, quality of life | No adverse events | 5 |
| Pinto et al | n=27 (men and women, healthy) | CR (5 g/day) or PLA | 12 wks | CR ↑ lean tissue mass | No adverse events | 4 |
| Tarnopolsky et al | n=39 (19 men; 20 women, healthy) | CR (5 g/day) + CLA (6 g/day) or PLA | 6 months | CR + CLA ↑ muscular endurance, isokinetic knee extension strength, lean tissue mass | One individual in the CR + CLA group reported gastrointestinal distress; no liver or kidney abnormalities | 5 |
| Villanueva et al | n=14 (healthy men) | CR (0.3 g/kg/day for 5 days, 0.07 g/kg/day thereafter + 35 g whey protein or PLA | 12 wks | ↔ lean tissue mass, chest press or leg press strength, chest press or leg press muscular endurance, Margaria power test, 400 m walking time | No adverse events | 2 |
Notes: ↑ represents significant increase compared with the placebo condition; ↔ represents no difference between the creatine and placebo conditions. Jadad scores range from 0 to 5 with 0 being poor quality and 5 being optimal quality.
Abbreviations: CR, creatine; IGF-1, insulin-like growth factor 1; PLA, placebo; PRO, protein; RT, resistance training; wk, week.
Figure 1Forest plots for lean tissue mass (A), chest press strength (B), and leg press stress (C).
Notes: Some studies presented data on men and women separately26,41 and on creatine and creatine + protein groups separately;21,22 therefore, these studies are entered twice in the meta-analysis for these separate subgroups. One study also presented data on participants who received creatine before versus after resistance training programs;28 therefore, these subgroups are entered separately in the meta-analysis.
Abbreviations: IV, inverse variance; Std, standardized; Cr, creatine.
Figure 2Potential mechanisms by which creatine supplementation leads to muscle hypertrophy.
Abbreviations: IGF-1, insulin-like growth factor 1; MRFs, myogenic regulatory factors; mTOR, mammalian target of rapamycin; PCr, phosphorylcreatine; ROS, reactive oxygen species; SC, satellite cells.
Figure 3Forest plots for phosphorylcreatine content in muscle of young and older adults for all studies (A) and for studies of only vastus lateralis (ie, studies of gastrocnemius or tibialis anterior were excluded from the analysis) (B).
Notes: One study presented data on men and women separately;62 therefore, these subgroups are entered separately in the meta-analysis. One study presented data for two different muscle groups;65 therefore, these are entered separately in the meta-analysis.
Abbreviations: IV, inverse variance; Std, standardized; TA, tibialis anterior; VL, vastus lateralis.